Related Experiment Video
Updated: May 2, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.2K
Adipocytes Impair Mitoxantrone Cytotoxicity Against Acute Lymphoblastic Leukemia
Michael Cohen1, Etan Orgel2,3, Jessica Nevarez-Mejia1
1Division of Pediatric Endocrinology UCLA Children's Discovery and Innovation Institute David Geffen School of Medicine University of California Los Angeles Los Angeles California USA.
Ejhaem
|September 2, 2025
Summary
Adipocytes cause chemotherapy resistance in acute lymphoblastic leukemia (ALL). Mitoxantrone did not overcome this resistance, suggesting it is not a viable alternative for obese patients with ALL.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Obesity is linked to worse outcomes in acute lymphoblastic leukemia (ALL).
- Adipocytes (fat cells) induce anthracycline resistance by metabolizing chemotherapy drugs.
- This resistance mechanism poses a challenge for treating ALL in obese patients.
Purpose of the Study:
- To investigate if mitoxantrone can overcome adipocyte-mediated chemoresistance in ALL.
- To compare the efficacy of mitoxantrone versus anthracyclines in the presence of adipocytes.
Main Methods:
- Human BV173 ALL cells were treated with daunorubicin and mitoxantrone.
- Drugs were incubated with or without 3T3-L1 adipocytes to mimic obesity.
- Chemoresistance was assessed by drug metabolism and cellular response.
Main Results:
- Adipocytes induced chemoresistance to both anthracyclines and mitoxantrone.
- Contrary to the hypothesis, mitoxantrone did not overcome adipocyte-mediated resistance.
- Drug metabolism pathways did not prevent adipocyte-induced resistance.
Conclusions:
- Mitoxantrone is unlikely to be an effective alternative to anthracyclines for overcoming adipocyte-mediated chemoresistance in ALL.
- Obesity-associated adipocytes present a significant challenge for chemotherapy efficacy in ALL patients.
